Coherus Oncology, Inc.
CHRS · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $42.2M | $26.4M | +59.8% |
| Operating income | −$181M | −$200M | +9.3% |
| Net income | $168M | $28.5M | +489% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $14.3M | $11.6M | +23.3% |
| Operating income | −$33.6M | −$44.3M | +24.2% |
| Net income | −$39.3M | −$35.5M | −10.7% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Coherus Oncology's revenue in FY2025?
- $42.2M in FY2025 (Fiscal year ended Dec 31, 2025), +59.8% vs $26.4M a year earlier, per its 10-K filed Mar 2026.
- Was Coherus Oncology profitable in FY2025?
- Yes: net income was $168M and operating income −$181M in FY2025.
- What was Coherus Oncology's revenue in Q3 2026?
- $14.3M (+23.3% vs a year earlier), per its Form 10-Q filed Nov 9, 2026.